Back

Cytoplasmic staining of T cell receptor components enables efficient assessment of lineage and clonality in surface CD3-negative T cell neoplasms

Wilk, A. J.; Gitana, G.; Oak, J.

2026-06-04 pathology
10.64898/2026.06.02.26354783 medRxiv
Show abstract

Flow cytometry can establish T cell clonality by detecting a restricted expression pattern of the T cell receptor (TCR) {beta} constant region (TRBC), expressed in association with CD3. However, T cell neoplasms frequently lose surface expression of the CD3/TCR complex, posing a challenge to demonstrating T cell lineage and clonality. To address this challenge, here we present a 12-color flow cytometry panel, called cytoTCR, to characterize cytoplasmic expression of CD3/TCR complex components. We apply cytoTCR to 38 patient specimens with immunophenotypically abnormal T cell populations, demonstrating this approach can efficiently establish T cell lineage and clonality in challenging T cell neoplasms that have lost surface CD3 expression. While we show that natural killer (NK)-lineage neoplasms can express cytoplasmic CD3 at similar levels to T cells, we show that absent expression of cytoplasmic TCR components by mature lymphocytes can help confirm NK cell lineage. We demonstrate that cytoTCR can detect cytoplasmic TRBC-restriction in challenging cases of null-phenotype anaplastic large cell lymphoma, which lack surface expression of pan-T cell antigens. In cases of T-lymphoblastic leukemia, cytoTCR shows that cytoplasmic TRBC expression matches the expected developmental stage of the leukemia. Finally, we use cytoTCR to characterize atypical cCD3-CD7- T cells in a patient with a history of T-lymphoblastic leukemia as well as recent CAR-T therapy, showing that this atypical population is polytypic and represents CAR-T product rather than residual disease. Our study presents a broadly applicable flow cytometric approach to simultaneously assess T cell lineage and clonality in suspected T lineage populations with absent surface CD3 expression.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Modern Pathology
21 papers in training set
Top 0.1%
28.0%
2
Cytometry Part A
30 papers in training set
Top 0.1%
12.5%
3
Blood Cancer Journal
11 papers in training set
Top 0.1%
8.5%
4
PLOS ONE
4510 papers in training set
Top 23%
7.3%
50% of probability mass above
5
Scientific Reports
3102 papers in training set
Top 28%
4.2%
6
Clinical Chemistry
22 papers in training set
Top 0.1%
3.6%
7
Cancers
200 papers in training set
Top 2%
3.6%
8
The Journal of Immunology
146 papers in training set
Top 0.6%
2.1%
9
Clinical Cancer Research
58 papers in training set
Top 0.8%
2.1%
10
Laboratory Investigation
13 papers in training set
Top 0.1%
1.9%
11
Journal of Pathology Informatics
13 papers in training set
Top 0.2%
1.7%
12
Journal of Clinical Pathology
12 papers in training set
Top 0.2%
1.7%
13
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.3%
1.3%
14
Frontiers in Immunology
586 papers in training set
Top 6%
0.9%
15
Leukemia
39 papers in training set
Top 0.7%
0.8%
16
British Journal of Haematology
15 papers in training set
Top 0.4%
0.8%
17
Blood
67 papers in training set
Top 1%
0.8%
18
Blood Advances
54 papers in training set
Top 1%
0.8%
19
eLife
5422 papers in training set
Top 57%
0.8%
20
PLOS Pathogens
721 papers in training set
Top 10%
0.7%
21
Communications Biology
886 papers in training set
Top 28%
0.7%
22
Heliyon
146 papers in training set
Top 8%
0.7%
23
Cells
232 papers in training set
Top 7%
0.7%
24
Cancer Research Communications
46 papers in training set
Top 2%
0.5%
25
iScience
1063 papers in training set
Top 40%
0.5%
26
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 49%
0.5%